Vaccination against Alzheimer disease

Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 – 2012)

(2013) Federica Belluti et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

(2013) Chia-Chen Liu et al.   Nature Reviews Neurology

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tau as a therapeutic target in neurodegenerative disease

(2012) Diana S. Himmelstein et al.   PHARMACOLOGY & THERAPEUTICS

Tau as a Therapeutic Target for Alzheimers Disease

(2011) A. Boutajangout et al.   Current Alzheimer Research

The Second-Generation Active A  Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

(2011) C. Wiessner et al.   JOURNAL OF NEUROSCIENCE

Optimization of the treatment regimen with active Aß immunotherapy CAD106 in alzheimer patients

(2010) Ana Graf et al.   Alzheimers & Dementia

The worldwide societal costs of dementia: Estimates for 2009

(2010) Anders Wimo et al.   Alzheimers & Dementia

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide

(2010) Stephanie J. Soscia et al.   PLoS One

Results of the first-in-man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients

(2009) Bengt G. Winblad et al.   Alzheimers & Dementia

Dementia incidence continues to increase with age in the oldest old: The 90+ study

(2009) María M. Corrada et al.   ANNALS OF NEUROLOGY

Tumour Necrosis Factor Modulation for Treatment of Alzheimerʼs Disease

(2009) Edward Tobinick   CNS DRUGS

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

(2009) Bruno Vellas et al.   Current Alzheimer Research

APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks

(2009) Stephan Röskam et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

S2-04-06: Safety, tolerability and immunogenicity of the Aβ immunotherapeutic vaccine CAD106 in a first-in-man study in Alzheimer patients

(2008) Bengt Winblad   Alzheimers & Dementia

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET